LS Investment Advisors LLC Invests $48,000 in Genomic Health, Inc. (NASDAQ:GHDX)

LS Investment Advisors LLC purchased a new position in Genomic Health, Inc. (NASDAQ:GHDX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 706 shares of the medical research company’s stock, valued at approximately $48,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of GHDX. Invesco Ltd. lifted its position in shares of Genomic Health by 316.4% in the second quarter. Invesco Ltd. now owns 687,787 shares of the medical research company’s stock worth $40,009,000 after purchasing an additional 522,627 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Genomic Health by 18.3% in the second quarter. Renaissance Technologies LLC now owns 2,814,500 shares of the medical research company’s stock worth $163,719,000 after buying an additional 435,000 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in Genomic Health in the second quarter worth approximately $25,290,000. Vanguard Group Inc. increased its holdings in Genomic Health by 12.1% in the second quarter. Vanguard Group Inc. now owns 2,828,265 shares of the medical research company’s stock worth $164,520,000 after buying an additional 305,047 shares during the last quarter. Finally, Man Group plc increased its holdings in Genomic Health by 47.5% in the second quarter. Man Group plc now owns 841,980 shares of the medical research company’s stock worth $48,978,000 after buying an additional 270,999 shares during the last quarter. 93.16% of the stock is owned by institutional investors and hedge funds.

In other news, CFO G Bradley Cole sold 60,000 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $73.31, for a total value of $4,398,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kimberly J. Popovits sold 50,000 shares of the firm’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.76, for a total value of $3,688,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 253,175 shares of company stock valued at $18,300,495. 31.30% of the stock is currently owned by corporate insiders.

A number of equities analysts recently commented on the company. Needham & Company LLC downgraded Genomic Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 30th. JPMorgan Chase & Co. upgraded Genomic Health from an “underweight” rating to a “neutral” rating and increased their price target for the company from $60.00 to $72.00 in a report on Monday, July 29th. Canaccord Genuity downgraded Genomic Health from a “buy” rating to a “hold” rating and lowered their price target for the company from $77.00 to $72.00 in a report on Tuesday, July 30th. Piper Jaffray Companies downgraded Genomic Health from an “overweight” rating to a “neutral” rating in a report on Monday, July 29th. Finally, Barclays upgraded Genomic Health from an “underweight” rating to an “equal weight” rating and increased their price target for the company from $45.00 to $72.00 in a report on Tuesday, July 30th. Ten equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $69.86.

Shares of GHDX stock opened at $63.44 on Friday. The company has a market cap of $2.46 billion, a PE ratio of 60.42 and a beta of 0.90. The business’s 50 day moving average is $68.48 and its two-hundred day moving average is $64.47. Genomic Health, Inc. has a 12 month low of $50.77 and a 12 month high of $90.18. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.15.

Genomic Health Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Story: What is an economic bubble?

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit